Logo image
Back
Respiratory Medications in Infants <29 Weeks during the First Year Postdischarge: The Prematurity and Respiratory Outcomes Program (PROP) Consortium
Journal article   Open access   Peer reviewed

Respiratory Medications in Infants <29 Weeks during the First Year Postdischarge: The Prematurity and Respiratory Outcomes Program (PROP) Consortium

Rita M Ryan, Roberta L Keller, Brenda B Poindexter, Carl T D'Angio, Pamela A Shaw, Scarlett L Bellamy, Paul E Moore, Christopher McPherson, James M Greenberg and PROP Investigators
The Journal of pediatrics, v 208, pp 148-155.e3
May 2019
DOI: https://doi.org/10.1016/j.jpeds.2018.12.009
PMID: 30857774
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://europepmc.org/articles/pmc6486865?pdf=renderView
Accepted (AM)Open Access (License Unspecified),  Open

Abstract

Administration, Inhalation Anti-Inflammatory Agents - administration & dosage Bronchodilator Agents - administration & dosage Bronchopulmonary Dysplasia - drug therapy Diuretics - administration & dosage Female Gestational Age Humans Infant Infant, Newborn Infant, Premature Infant, Premature, Diseases - drug therapy Intensive Care Units, Neonatal Male Oxygen - therapeutic use Patient Discharge Prednisone - administration & dosage Prospective Studies Steroids - administration & dosage Surveys and Questionnaires Treatment Outcome
To determine patterns of respiratory medications used in neonatal intensive care unit graduates. The Prematurity Respiratory Outcomes Program enrolled 835 babies <29 weeks of gestation in the first week. Of 751 survivors, 738 (98%) completed at least 1, and 85% completed all 4, postdischarge medication usage in-person/telephone parental questionnaires requested at 3, 6, 9, and 12 months of corrected age. Respiratory drug usage over the first year of life after in neonatal intensive care unit discharge was analyzed. During any given quarter, 66%-75% of the babies received no respiratory medication and 45% of the infants received no respiratory drug over the first year. The most common postdischarge medication was the inhaled bronchodilator albuterol; its use increased significantly from 13% to 31%. Diuretic usage decreased significantly from 11% to 2% over the first year. Systemic steroids (prednisone, most commonly) were used in approximately 5% of subjects in any one quarter. Inhaled steroids significantly increased over the first year from 9% to 14% at 12 months. Drug exposure changed significantly based on gestational age with 72% of babies born at 23-24 weeks receiving at least 1 respiratory medication but only 40% of babies born at 28 weeks. Overall, at some time in the first year, 55% of infants received at least 1 drug including an inhaled bronchodilator (45%), an inhaled steroid (22%), a systemic steroid (15%), or diuretic (12%). Many babies born at <29 weeks have no respiratory medication exposure postdischarge during the first year of life. Inhaled medications, including bronchodilators and steroids, increase over the first year.

Metrics

6 Record Views
30 citations in Web of Science
29 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Pediatrics
Logo image